---
import BaseLayout from '../layouts/BaseLayout.astro';
import { Icon } from 'astro-icon/components';
---

<BaseLayout title="ASPS - Alveolar Soft Part Sarcoma" description="Understanding ASPS: The ultra-rare fusion-driven cancer. Driven by ASPSCR1-TFE3. A deterministic target for precision medicine.">
    <div slot="head">
        <link href="https://fonts.googleapis.com" rel="preconnect"/>
        <link crossorigin="" href="https://fonts.gstatic.com" rel="preconnect"/>
        <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700;800&display=swap" rel="stylesheet"/>
    </div>

  <!-- Fixed Background Layer -->
  <div class="fixed inset-0 z-0 pointer-events-none bg-ref-bg-light dark:bg-ref-bg-dark transition-colors duration-300">
      <div class="absolute inset-0 bg-[linear-gradient(to_right,#80808012_1px,transparent_1px),linear-gradient(to_bottom,#80808012_1px,transparent_1px)] bg-[size:24px_24px]"></div>
      <div class="absolute left-0 right-0 top-0 -z-10 m-auto h-[500px] w-[500px] rounded-full bg-purple-500/20 opacity-50 blur-[100px]"></div>
  </div>

  <!-- Scrollable Content Layer -->
  <div class="relative z-10 text-slate-800 dark:text-slate-200 font-sans">
    
    <!-- Header Section -->
    <header class="relative pt-6 pb-16 w-full">
        <div class="max-w-[90%] mx-auto px-4 sm:px-6 lg:px-8 text-center">
            <h1 class="text-4xl md:text-6xl font-extrabold text-slate-900 dark:text-white tracking-tight mb-6 leading-tight">
                <span class="text-transparent bg-clip-text bg-gradient-to-r from-ref-primary to-indigo-600 dark:from-purple-400 dark:to-indigo-400">
                    ASPS: The Disease
                </span>
            </h1>
            <p class="max-w-3xl mx-auto text-lg md:text-xl text-slate-600 dark:text-slate-400 leading-relaxed">
                Ultra-rare, fusion-driven, and deterministic. Alveolar Soft Part Sarcoma and the ASPSCR1-TFE3 driver.
            </p>
        </div>
    </header>

    <main class="max-w-[85%] mx-auto px-4 sm:px-6 lg:px-8 pb-24 space-y-16">
        
        <!-- What is ASPS -->
        <section class="relative group">
            <div class="absolute -inset-4 bg-gradient-to-r from-purple-50 to-indigo-50 dark:from-slate-800/50 dark:to-slate-900/50 rounded-[2.5rem] -z-10 opacity-50 blur-xl transition duration-500 group-hover:opacity-100"></div>
            <div class="bg-ref-surface-light dark:bg-ref-surface-dark rounded-2xl p-8 md:p-12 shadow-xl border border-slate-200 dark:border-slate-700">
                <div class="flex items-center gap-3 mb-6">
                    <div class="p-2 bg-blue-100 dark:bg-blue-900/50 rounded-lg text-blue-600">
                        <Icon name="mdi:information" class="w-6 h-6" />
                    </div>
                    <h2 class="text-2xl font-bold text-slate-900 dark:text-white">What is ASPS?</h2>
                </div>
                <p class="text-lg text-slate-600 dark:text-slate-300 mb-6 leading-relaxed">
                    Alveolar Soft Part Sarcoma (ASPS) is an ultra-rare, malignant soft tissue sarcoma that primarily strikes adolescents and young adults. Unlike common cancers that arise from decades of cellular aging or environmental damage, ASPS is driven by a specific, catastrophic genetic accident.
                </p>
                <p class="text-slate-600 dark:text-slate-300 mb-6 leading-relaxed">
                    It is a disease of contradictions: it grows slowly (indolent) but spreads aggressively (metastatic). It often arises deep within the muscles of the limbs in adults, or the head and neck in children, frequently going unnoticed until it has already traveled to the lungs or brain.
                </p>
                <div class="bg-blue-50 dark:bg-blue-900/20 border border-blue-200 dark:border-blue-800/30 rounded-lg p-4">
                    <p class="text-sm text-blue-900 dark:text-blue-100">
                        <span class="font-semibold">Epidemiology:</span> Represents &lt;1% of all soft tissue sarcomas. ~80 cases diagnosed annually in the United States. Affects primarily 15-35 year olds, slightly more common in females.
                    </p>
                </div>
            </div>
        </section>

        <!-- The Biological Driver -->
        <section class="relative group">
            <div class="absolute -inset-4 bg-gradient-to-r from-green-50 to-emerald-50 dark:from-slate-800/50 dark:to-slate-900/50 rounded-[2.5rem] -z-10 opacity-50 blur-xl transition duration-500 group-hover:opacity-100"></div>
            <div class="bg-ref-surface-light dark:bg-ref-surface-dark rounded-2xl p-8 md:p-12 shadow-xl border border-slate-200 dark:border-slate-700">
                <div class="flex items-center gap-3 mb-6">
                    <div class="p-2 bg-green-100 dark:bg-green-900/50 rounded-lg text-green-600">
                        <Icon name="mdi:dna" class="w-6 h-6" />
                    </div>
                    <h2 class="text-2xl font-bold text-slate-900 dark:text-white">The Biological Driver: The Fusion</h2>
                </div>
                <p class="text-slate-600 dark:text-slate-300 mb-6 leading-relaxed">
                    While most cancers are chaotic, ASPS is deterministic. It is caused by a single chromosomal translocation: <span class="font-semibold">t(X;17)(p11;q25)</span>, which fuses two genes that should never meet: <span class="font-semibold">ASPSCR1</span> and <span class="font-semibold">TFE3</span>.
                </p>
                <p class="text-slate-600 dark:text-slate-300 mb-6 leading-relaxed">
                    This creates a chimeric oncoprotein, <span class="font-semibold">ASPSCR1-TFE3</span>, which acts as a molecular dictator:
                </p>
                
                <div class="grid md:grid-cols-3 gap-4">
                    <div class="bg-white dark:bg-slate-800 rounded-xl p-4 border border-slate-100 dark:border-slate-700">
                        <h3 class="font-bold text-slate-900 dark:text-white mb-2 text-sm">Nuclear Hijacking</h3>
                        <p class="text-sm text-slate-600 dark:text-slate-300">
                            The fusion protein enters the cell nucleus and stays there, overriding normal safety switches.
                        </p>
                    </div>
                    <div class="bg-white dark:bg-slate-800 rounded-xl p-4 border border-slate-100 dark:border-slate-700">
                        <h3 class="font-bold text-slate-900 dark:text-white mb-2 text-sm">Epigenetic Rewiring</h3>
                        <p class="text-sm text-slate-600 dark:text-slate-300">
                            It recruits massive cellular machinery (Super-Enhancers and VCP/p97) to restructure the genome.
                        </p>
                    </div>
                    <div class="bg-white dark:bg-slate-800 rounded-xl p-4 border border-slate-100 dark:border-slate-700">
                        <h3 class="font-bold text-slate-900 dark:text-white mb-2 text-sm">The Result</h3>
                        <p class="text-sm text-slate-600 dark:text-slate-300">
                            Activation of unlimited growth and massive blood vessel creation (angiogenesis).
                        </p>
                    </div>
                </div>
            </div>
        </section>

        <!-- Why is it Hard to Treat -->
        <section>
            <div class="text-center mb-10">
                <h2 class="text-3xl font-bold text-slate-900 dark:text-white mb-4">Why is it So Hard to Treat?</h2>
                <p class="max-w-2xl mx-auto text-slate-600 dark:text-slate-400">
                    ASPS presents unique challenges to modern oncology.
                </p>
            </div>
            <div class="grid md:grid-cols-3 gap-6">
                <div class="bg-white dark:bg-slate-800 rounded-2xl p-6 shadow-lg border border-slate-200 dark:border-slate-700">
                    <div class="flex items-center gap-3 mb-4">
                        <div class="p-2 bg-red-100 dark:bg-red-900/30 rounded-lg text-red-600">
                            <Icon name="mdi:pill" class="w-5 h-5" />
                        </div>
                        <h3 class="font-bold text-slate-900 dark:text-white">Chemotherapy Resistance</h3>
                    </div>
                    <p class="text-sm text-slate-600 dark:text-slate-300">
                        Standard sarcoma chemotherapies (like Doxorubicin) are largely ineffective against ASPS.
                    </p>
                </div>
                <div class="bg-white dark:bg-slate-800 rounded-2xl p-6 shadow-lg border border-slate-200 dark:border-slate-700">
                    <div class="flex items-center gap-3 mb-4">
                        <div class="p-2 bg-orange-100 dark:bg-orange-900/30 rounded-lg text-orange-600">
                            <Icon name="mdi:briefcase" class="w-5 h-5" />
                        </div>
                        <h3 class="font-bold text-slate-900 dark:text-white">Orphan Disease Status</h3>
                    </div>
                    <p class="text-sm text-slate-600 dark:text-slate-300">
                        Affects so few people that there is minimal commercial incentive for pharma to develop dedicated drugs.
                    </p>
                </div>
                <div class="bg-white dark:bg-slate-800 rounded-2xl p-6 shadow-lg border border-slate-200 dark:border-slate-700">
                    <div class="flex items-center gap-3 mb-4">
                        <div class="p-2 bg-purple-100 dark:bg-purple-900/30 rounded-lg text-purple-600">
                            <Icon name="mdi:blood-bag" class="w-5 h-5" />
                        </div>
                        <h3 class="font-bold text-slate-900 dark:text-white">Vascular Shielding</h3>
                    </div>
                    <p class="text-sm text-slate-600 dark:text-slate-300">
                        The tumor creates a dense network of blood vessels, making it resilient and prone to early metastasis.
                    </p>
                </div>
            </div>
        </section>

        <!-- Current Treatment & Sarkome Strategy -->
        <section class="bg-ref-surface-light dark:bg-ref-surface-dark rounded-2xl p-8 md:p-12 shadow-xl border border-slate-200 dark:border-slate-700">
            <div class="grid md:grid-cols-2 gap-12">
                <div>
                    <div class="flex items-center gap-3 mb-6">
                        <div class="p-2 bg-yellow-100 dark:bg-yellow-900/30 rounded-lg text-yellow-600">
                            <Icon name="mdi:hospital-box" class="w-6 h-6" />
                        </div>
                        <h2 class="text-2xl font-bold text-slate-900 dark:text-white">Current Treatment</h2>
                    </div>
                    <p class="text-slate-600 dark:text-slate-300 mb-4 leading-relaxed">
                        Patients currently rely on <span class="font-semibold">Atezolizumab</span> (immunotherapy) and TKIs. While these can stabilize disease, they are rarely curative.
                    </p>
                    <p class="text-slate-600 dark:text-slate-300 leading-relaxed">
                        <span class="text-red-600 dark:text-red-400 font-semibold">The Problem:</span> These treat the symptoms (blood vessels) rather than the root cause, the fusion itself.
                    </p>
                </div>
                <div>
                    <div class="flex items-center gap-3 mb-6">
                        <div class="p-2 bg-green-100 dark:bg-green-900/30 rounded-lg text-green-600">
                            <Icon name="mdi:lightbulb-on" class="w-6 h-6" />
                        </div>
                        <h2 class="text-2xl font-bold text-slate-900 dark:text-white">Sarkome Strategy</h2>
                    </div>
                    <p class="text-slate-600 dark:text-slate-300 mb-4 leading-relaxed">
                        We use GenDiscovery to find molecules that target the <span class="font-semibold">ASPSCR1-TFE3 fusion itself</span> and its structural dependencies, specifically the <span class="font-semibold">VCP complex</span>.
                    </p>
                    <p class="text-slate-600 dark:text-slate-300 leading-relaxed">
                        <span class="text-green-600 dark:text-green-400 font-semibold">The Goal:</span> Induce a synthetic lethal collapse of the tumor by breaking the machinery the fusion uses to survive.
                    </p>
                </div>
            </div>
        </section>

    </main>
  </div>
</BaseLayout>
